-+ 0.00%
-+ 0.00%
-+ 0.00%

Invivyd doses first participants in Phase 3 LIBERTY trial of VYD2311 vs mRNA COVID vaccine

PUBT·06/09/2026 11:02:24
Listen to the news
Invivyd doses first participants in Phase 3 LIBERTY trial of VYD2311 vs mRNA COVID vaccine
  • Invivyd dosed the first participants in LIBERTY, a Phase 3 head-to-head trial of its VYD2311 antibody versus an mRNA COVID-19 vaccine.
  • Topline results have not been presented; reporting is expected in Q3 2026, alongside anticipated data from the pivotal DECLARATION trial.
  • Study aims to compare short-term tolerability, focusing on side effects and reactions, to position VYD2311 as a vaccine alternative.
  • Trial also evaluates co-administration with an mRNA vaccine, testing whether combined use remains acceptable from a safety and immune-response perspective.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606090701PRIMZONEFULLFEED9733793) on June 09, 2026, and is solely responsible for the information contained therein.